Calidi Biotherapeutics is offering 1,025,640 common shares at $1.17 each, targeting approximately $1.1 million in net proceeds. Investors should note the funds are intended for Working Capital and corporate purposes, while the company says additional financing is needed to sustain operations and raises substantial doubt about going concern.
Key Highlights
- Calidi Biotherapeutics expects approximately $1.1 million in net proceeds after estimated offering expenses.
- The securities sale covers 1,025,640 common shares priced at $1.17 each.
- The company expects 3,685,849 common shares to be outstanding after the offering.
Calidi Biotherapeutics, Inc. (AMEX: CLDI) is a biotechnology company. It is offering 1,025,640 shares of Common Stock at $1.17 per share, with estimated net proceeds of approximately $1.1 million after offering expenses.
$1.17 Share Sale Sets Post-Offering Count
The expected post-offering share count is 3,685,849, including 9,375 non-voting Escalation Shares, compared with a September 16, 2026 base of 2,660,209 shares that also includes 9,375 such shares. Calidi Biotherapeutics says it will direct the proceeds toward working capital and general corporate purposes, including advancing pre-clinical and clinical programs. The company says it will not pay placement-agent fees, Underwriting discounts or commissions for the offering.
Capital Needs Remain a Stated Risk
Recurring operating losses and the need for additional funding raise substantial doubt about its ability to continue as a going concern.
FAQs
Q: How many shares is Calidi Biotherapeutics offering and at what price?
A: Calidi Biotherapeutics is offering 1,025,640 shares of Common Stock at $1.17 per share. The securities purchase agreement is dated September 17, 2026.
Q: What outstanding warrants and options are excluded from Calidi Biotherapeutics’ share count?
A: The article does not state which outstanding warrants or options are excluded, nor does it provide their share amounts or exercise prices. It only states that the expected post-offering count is 3,685,849 shares, including 9,375 non-voting Escalation Shares.
Q: Does Calidi Biotherapeutics currently pay cash dividends?
A: Calidi Biotherapeutics has never declared or paid cash dividends on its capital stock. The company does not currently intend to pay dividends on its Common Stock for the foreseeable future.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.